The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts

(1) Background: Fidaxomicin has been shown to significantly reduce <i>Clostridioides difficile</i> infection (CDI) recurrences rates in randomized, controlled trials. However, national data from the Veterans Affairs has called the real-world applicability of these findings into question. Therefore,...

Descripción completa

Detalles Bibliográficos

Autores principales:	Ronald G. Hall, Travis J. Cole, Chip Shaw, Carlos A. Alvarez
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2022-02-01
Colección:	Antibiotics
Materias:	fidaxomicin vancomycin <i>Clostridioides difficile</i> CDI recurrence
Acceso en línea:	https://www.mdpi.com/2079-6382/11/3/295
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!